Non-Alcoholic Fatty Liver Disease Is Associated with Impairment of Ejection Fraction Among Individuals with Obesity Undergoing Bariatric Surgery: Results of a Cross-Sectional Study
ConclusionAmong individuals with morbid obesity, the findings of this study are suggestive that liver fibrosis confirmed by histopathological examination is associated with a slight impairment of left ventricular function. Further studies are needed to confirm this association.
We report a case of a post RYGB patient with severe malnutrition who developed non-alcoholic fatty liver disease. Severe chronic malnutrition predisposed by bariatric surgery is considered as potential mechanism of hepatic steatosis. Liver function should be routinely monitored for post bariatric patients with nutritional risk. Proper enteral and parenteral nutrition support can be a major treatment for hepatic steatosis induced by severe malnutrition.
Non-alcoholic fatty liver disease (NAFLD) is a common chronic progressive parenchymal liver disease with strong pathophysiological underpinnings to adiposity-based chronic disease or obesity. One of the hallmarks of the disease is an insulin-resistant state driven by increased body fat promoting adipose tissue dysfunction, a chronic inflammatory state, altered gut mucosal barrier and microbiome, and permissive abnormal signaling between the central nervous system and peripheral metabolic organs.
Bariatric surgery is still not recommended to alleviate the long-term sequelae of non-alcoholic fatty liver disease (NAFLD) despite some evidence to suggest bariatric surgery can mitigate the risk of non-alcoholic steatohepatitis (NASH) and/or hepatocellular carcinoma. This current study is the first to use a propensity match analysis of a large cohort of bariatric surgery patients with non-surgery controls to show that patients who had undergone bariatric surgery had fewer new cases of NASH and HCC with extended follow up, and further risk adjustment also revealed bariatric surgery was associated with fewer cases of NASH ...
ConclusionsIntraoperative liver biopsy during bariatric surgery is safe and identified liver disease in 89%, with 9% meeting referral criteria. Pasifika patients have a higher rate of NAFLD than non-Pasifika.
A low calorie diet (LCD) prior to bariatric surgery has been shown to reduce liver volume and facilitate ease of operation. It is estimated that 75 -100% of individuals undergoing bariatric surgery have non-alcoholic fatty liver disease (NAFLD).
We read with interest the recent paper by Styczy ński and coworkers . Their findings revealed no significant association between non-alcoholic fatty liver disease (NAFLD) on wedge liver biopsy and an increased arterial stiffness – as reflected by aortic pulse wave velocity (PWV) – in a sample of 120 morbidly obese patients. The authors are to be congratulated for specifically examining this issue in a high-risk clinical population of patients who were consecutively admitted for bariatric surgery.
Over the past 10 years bariatric surgeons have embraced our role in not only producing sustained and long-term weight loss, but more importantly we have embraced our role in improving metabolic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD). With obesity increasing worldwide we have seen a concomitant increase in patients with the progression of NAFLD to nonalcoholic steatohepatitis (NASH) and ultimately cirrhosis . Although we have more and more evidence of remission of NAFLD and NASH, liver biopsy remains the gold standard for tracking regression and remission.
This study aims to determine the effect of type 2 diabetes mellitus and insulin therapy on non-alcoholic fatty liver disease in the patients with morbid obesity. MATERIAL AND METHODS: Clinical, anthropometric and laboratory data were analyzed together with intraoperative liver biopsies from morbidly obese patients undergoing bariatric surgery. RESULTS: 219 patients with morbid obesity were evaluated. Systemic arterial hypertension (55.9% vs. 33.8%, p = 0.004) and dyslipidemia (67.1% vs. 39.0%, p
AbstractNon-alcoholic fatty liver disease (NAFLD) pathogenesis associates with intramyocellular lipid deposition and mitochondrial dysfunction. microRNAs (miRs), including pro-apoptotic miR-34a, are modulated during disease progression in liver tissue and plasma. We aimed to investigate the functional role of the miR-34a/SIRT1:AMP-activated protein kinase (AMPK) pathway in modulating local mitochondrial dysfunction in the skeletal muscle of human and experimental non-alcoholic steatohepatitis. Muscle biopsies were obtained from morbid obese NAFLD patients undergoing bariatric surgery. C57BL/6N mice were fed different NAFLD...
Conclusions: While there is a certain overlap between the results of the current study and published transcriptomic profiles of non-transplanted livers with steatosis, we have identified discrete characteristics of the non-alcoholic fatty liver disease in liver grafts potentially utilizable for the establishment of predictive signature. Introduction Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in industrialized countries, its prevalence being estimated at 19–31.3% (1). It encompasses a range of conditions that are thought to arise from fatty liver (simple steatosis) throu...